Search results for " trials"

showing 10 items of 932 documents

NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYO…

2017

Irritable bowel syndrome (IBS) is a chronic, recurring, and remitting functional disorder of the gastrointestinal tract characterized by abdominal pain, distention, and changes in bowel habits. Although there are several drugs for IBS, effective and approved treatments for one or more of the symptoms for various IBS subtypes are needed. Improved understanding of pathophysiological mechanisms such as the role of impaired bile acid metabolism, neurohormonal regulation, immune, dysfunction, the epithelial barrier and the secretory properties of the gut has led to advancements in the treatment of IBS. With regards to therapies for restoring intestinal permeability, multiple studies with prebiot…

Abdominal painmedicine.medical_specialtyReviewFunctional disorderGastroenterologyPermeabilityBile Acids and Salts03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGastrointestinal AgentsMesalazineInternal medicineImmunoendocrine axisTherapy; Low grade inflammation; Motility; Secretion; Irritable bowel syndrome; Immunoendocrine axismedicineHumansSecretionIrritable bowel syndromeInflammationClinical Trials as TopicGastrointestinal agentSettore MED/12 - GastroenterologiaLow grade inflammationIntestinal permeabilitybusiness.industryGastroenterologyMotilityDrugs InvestigationalGeneral Medicinemedicine.diseaseAbdominal PainRifaximinIntestinesClinical trialIrritable bowel syndromeSettore MED/18 - Chirurgia GeneraleTreatment Outcomechemistry030220 oncology & carcinogenesis030211 gastroenterology & hepatologyTherapymedicine.symptomGastrointestinal Motilitybusiness
researchProduct

Clinical results of transanal endoscopic microsurgery

1988

Using the "transanal endoscopic microsurgery" technique, 140 patients were treated at the Department of Surgery in Cologne and Mainz. Of the patients with adenomas, 68.2% had typical symptoms preoperatively. The postoperative hospital attendance was 8.7 days, with an average resection size of 14.4 cm2. The postoperative complication rate was 5%, and there were no deaths related to the technique. In a prospective controlled trial, 2.2% of the patients with adenomas treated endoscopically in Mainz showed recidivation, requiring reoperation. The follow-up rate was 100%. In 30 cases, microscopic examination revealed carcinoma. Radical reoperation in 8 pT1 tumours showed neither remaining tumour…

AdenomaReoperationMicrosurgerymedicine.medical_specialtyAdenomamedicine.medical_treatmentRectummedicineCarcinomaHumansProspective StudiesLymph nodeClinical Trials as Topicmedicine.diagnostic_testRectal Neoplasmsbusiness.industryIntestinal PolypsPostoperative complicationColonoscopyMicrosurgerymedicine.diseaseEndoscopySurgerymedicine.anatomical_structureColonic NeoplasmsSurgeryNeoplasm Recurrence LocalbusinessAbdominal surgerySurgical Endoscopy
researchProduct

Relation between health literacy, self-care and adherence to treatment with oral anticoagulants in adults: a narrative systematic review

2018

Background Oral anticoagulants (OAC) are widely used in patients with cardiovascular diseases. However, for optimal OAC self-care patients must have skills, among which health literacy (HL) is highlighted. We aimed to describe the relation between HL and self-care in cardiovascular patients on OAC treatment. Methods Electronic searches were carried out in the PubMed, Scopus, Embase, CINAHL, Web of Science, Cochrane Library, SciELO, IME-Biomedicina, CUIDEN Plus and LILACS databases, limited to Spanish and English language and between January 2000–December 2016. Papers reported on adults older than 18 years, taking OAC by themselves for at least three months. PRISMA guidelines were used for p…

Administration OralSalud030204 cardiovascular system & hematologyCochrane Library0302 clinical medicineEpidemiology030212 general & internal medicinePublic Environmental & Occupational HealthRandomized Controlled Trials as TopicOUTCOMESSelf-managementWARFARIN THERAPYNarrationlcsh:Public aspects of medicineASSOCIATIONCor Malalties1117 Public Health And Health ServicesCardiovascular DiseasesHEART-FAILUREPublic HealthSelf-careLife Sciences & BiomedicineResearch Articlemedicine.drugAdultmedicine.medical_specialtyHealth literacyCINAHLMedication Adherence03 medical and health sciencesMEDICATIONmedicineSelf-managementMANAGEMENTQUALITYHumansKNOWLEDGEScience & Technologybusiness.industryPublic healthMORTALITYPublic Health Environmental and Occupational HealthWarfarinHealth literacyAnticoagulantslcsh:RA1-1270R1Self CareAdherenceFamily medicineATRIAL-FIBRILLATIONAnticoagulants (Medicina)Systematic reviewOral coagulation therapyBiostatisticsbusinessRA
researchProduct

Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

2018

Abstract Background Retrospective data suggest better outcomes for patients with double hormonal receptor (oestrogen [ER] and progesterone receptor [PgR])–positive (dHR+) early breast cancer, compared with single hormonal receptor–positive, sHR+, (ER+/PgR– or ER–/PgR+) disease. Here, we evaluate the classification according to intrinsic subtypes and clinical outcomes of sHR+ versus dHR+ in HER2-negative breast cancer patients enrolled in GEICAM/9906 study ( NCT00129922 ). Methods Archival tumours were retrieved retrospectively for the analysis of ER, PgR and HER2 status and classified into intrinsic subtypes using the PAM50 gene expression assay. Disease-free survival (DFS) and overall surv…

Adult0301 basic medicineOncologyendocrine systemCancer Researchmedicine.medical_specialtyPaclitaxelBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsProgesterone receptormedicineHumansPAM50Single receptor positiveskin and connective tissue diseasesReceptorCyclophosphamideAgedEpirubicinProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesHormone receptor positivebusiness.industryIncidence (epidemiology)Hazard ratioLuminal aMiddle Agedmedicine.disease030104 developmental biologyClinical Trials Phase III as TopicReceptors EstrogenOncologyIntrinsic subtypesHormone receptor030220 oncology & carcinogenesisFemaleFluorouracilReceptors ProgesteroneTranscriptomebusinesshormones hormone substitutes and hormone antagonistsHormoneEuropean Journal of Cancer
researchProduct

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

2016

// Daniela Massihnia 1,* , Antonio Galvano 1,* , Daniele Fanale 1 , Alessandro Perez 1 , Marta Castiglia 1 , Lorena Incorvaia 1 , Angela Listi 1 , Sergio Rizzo 1 , Giuseppe Cicero 1 , Viviana Bazan 1 , Sergio Castorina 2,3,** and Antonio Russo 1,** 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 3 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy * These authors have contributed equally to this work ** Both the authors are last name Correspondence to: Antonio Russo, email: // Keywords : ER, HER2, PI3K/AKT/mTOR inhib…

Adult0301 basic medicineOncologymedicine.medical_specialtyPathologyAntineoplastic AgentsTriple Negative Breast NeoplasmsReviewTarget therapyPhosphatidylinositol 3-Kinases03 medical and health sciences0302 clinical medicineBreast cancerHER2Internal medicineDrug DiscoverymedicineCarcinomaHumansTriple negative breast cancerTarget therapyER; HER2; PI3K/AKT/mTOR inhibitor; Target therapy; Triple negative breast cancer; OncologySurvival rateProtein kinase BPI3K/AKT/mTOR pathwayTriple-negative breast cancerAgedClinical Trials as Topicbusiness.industryTOR Serine-Threonine KinasesAge FactorsMiddle Agedmedicine.diseaseOncogene Protein v-aktClinical trial030104 developmental biologyEROncology030220 oncology & carcinogenesisFemalePI3K/AKT/mTOR inhibitorbusinessSignal TransductionOncotarget
researchProduct

Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum

2019

Abstract: Lifestyle modification is the foundation of treatment recommendations for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The design of clinical trials in NASH may be impeded by the lack of a systematic approach to identify and evaluate how lifestyle changes and/or modifications influence clinical trial outcomes and associated endpoints. Furthermore, there are additional uncertainties regarding the methods that can be utilised to better characterise and quantify lifestyle variables - which can influence disease activity and alter trial endpoints - to allow for comparisons of trial outcomes across different phases of research and/or within drug-c…

Adult0301 basic medicinemedicine.medical_specialtyStandard of careContext (language use)DiseaseBody Mass IndexDisease activity03 medical and health sciences0302 clinical medicineLifestyle modificationNon-alcoholic Fatty Liver DiseaseHumansMedicineIntensive care medicineExerciseClinical Trials as TopicHepatologybusiness.industryBody WeightFatty livermedicine.diseaseExercise TherapyClinical trialTreatment Outcome030104 developmental biology030211 gastroenterology & hepatologyHuman medicineDiet HealthyWaist CircumferenceSteatohepatitisbusinessJournal of Hepatology
researchProduct

[Herpes Zoster and its prevention in Italy. Scientific consensus statement].

2014

In this paper, an Italian group of experts presents a revision of the available data about epidemiology and prevention of Herpes Zoster (HZ). HZ is an acute viral diseases caused by the reactivation of Varicella Zoster Virus (VZV). HZ is characterized by neurological and dermatological symptoms with a dermatomeric localization. The reactivation of the virus from the latent status in the sensitive ganglia increases with age and failing cell mediated immunity. In Europe, more than 95% of adults presents antibodies against VZV. Incidence of HZ is similar all over the world, related to the age of the population: from 2-3/1000 persons/year in the age group 20 to 50 years to 5/1000 in the 60 year…

AdultAged 80 and overClinical Trials as TopicEvidence-Based MedicineSettore MED/17 - Malattie InfettiveIncidenceSocio-culturaleNeuralgia Postherpeticconsensus statementMiddle AgedSettore MED/42 - Igiene Generale E ApplicataHerpes ZosterAge DistributionItalyRisk Factors80 and overNeuralgiaHerpes Zoster VaccineHumansAdult; Age Distribution; Aged; Aged 80 and over; Clinical Trials as Topic; Evidence-Based Medicine; Herpes Zoster; Herpes Zoster Vaccine; Humans; Incidence; Italy; Middle Aged; Neuralgia Postherpetic; Risk Factors; SicilyPostherpeticSicilyprevention of herpes zosterAgedIgiene e sanita pubblica
researchProduct

Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease.

2008

1. Aliment Pharmacol Ther. 2008 Jun;27(12):1210-23. Epub 2008 Mar 14. Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. Tinè F, Rossi F, Sferrazza A, Orlando A, Mocciaro F, Scimeca D, Olivo M, Cottone M. Divisione di Gastroenterologia, Azienda Ospedaliera V. Cervello, Palermo, Italy. fabiotinemd@virgilio.it BACKGROUND: Remission and response are the main outcomes to evaluate the efficacy of new treatments for Crohn's disease (CD). AIM: To explain variation of remission and response rates in active luminal CD. METHODS: We studied control patients from trials of biological therapies through articles retriev…

AdultBiological TherapyMalePlacebosTreatment Outcomemetanalysis. biologics.crohn's diseaseCrohn DiseaseDose-Response Relationship DrugRemission InductionHumansFemaleRandomized Controlled Trials as Topic
researchProduct

Erratum: Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: a systematic review and meta-analysis of do…

2016

Although higher dietary intakes of magnesium (Mg) seem to correspond to lower diabetes incidence, research concerning Mg supplementation in people with or at risk of diabetes is limited. Thus, we aimed to investigate the effect of oral Mg supplementation on glucose and insulin-sensitivity parameters in participants with diabetes or at high risk of diabetes compared with placebo. A literature search in PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials and Clinicaltrials.gov without language restriction, was undertaken. Eligible studies were randomized controlled trials (RCTs) investigating the effect of oral Mg supplementation vs placebo in patients with diabetes or at h…

AdultBlood GlucoseMale0301 basic medicinemedicine.medical_specialtyCalorieMagnesium supplementationMedicine (miscellaneous)030209 endocrinology & metabolismCarbohydrate metabolismlaw.inventionDouble blind03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumansMagnesiumAgedRandomized Controlled Trials as TopicGlucose tolerance test030109 nutrition & dieteticsNutrition and Dieteticsmedicine.diagnostic_testbusiness.industryMedicine (all)Medicine (miscellaneous); Medicine (all); Nutrition and DieteticsFastingGlucose Tolerance TestMiddle Agedmedicine.diseaseObesityEndocrinologyMeta-analysisDietary Supplementsmagnesium Nutrition diabetes Dietetics glucose metabolismFemalebusinessBody mass indexEuropean Journal of Clinical Nutrition
researchProduct

Glucose control in the older patient: from intensive, to effective and safe.

2009

Older adults represent an extensive proportion of Type 2 diabetic patients. Managing diabetes in this population is challenging, because complex comorbidity and disability often mean that guidelines are not suitable on an individual basis. Recent evidence has raised animated discussion of the possibility that intensive glucose control may cause more harm than benefit, especially in older adults. The benefit of glycemic control on microvascular diabetic complications has been consistently demonstrated, but the evidence of benefit on macrovascular disease is not uniform in all studies. Glycemic control appears to prevent the development of cardiovascular events, but is less helpful in seconda…

AdultBlood GlucoseMaleAgingmedicine.medical_specialtyPopulationType 2 diabetesHypoglycemiaDiabetes ComplicationsDiabetes mellitusNeoplasmsmedicineDementiaHumansHypoglycemic AgentsInsulinIntensive care medicineeducationMacrovascular diseaseGlycemicAgedRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryAge FactorsMiddle Agedmedicine.diseaseComorbidityHypoglycemiaDiabetes Mellitus Type 2Accidental FallsDementiaFemaleGeriatrics and GerontologybusinessAging clinical and experimental research
researchProduct